Pharmaceuticals, Biotechnology and Life Sciences
Demonstrated tangible market progress and shipped 17 instruments through year end 2021REDWOOD CITY, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) —…
Late-breaking data at 2022 AAAAI Annual Meeting show Dupixent® (dupilumab) significantly improved signs and symptoms of eosinophilic esophagitis Dupixent 300…
Late-breaking phase 3 data at 2022 AAAAI Annual Meeting show Dupixent® (dupilumab) significantly reduced itch and hives in patients with…
THE WOODLANDS, Texas, Feb. 25, 2022 (GLOBE NEWSWIRE) — Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), will release its fourth quarter 2021…
WARREN, N.J., Feb. 24, 2022 (GLOBE NEWSWIRE) — Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to solve…
Company working to accelerate lead clinical programs; expects multiple clinical readouts in 2022WESTPORT, Conn., Feb. 24, 2022 (GLOBE NEWSWIRE) —…
Recent independent Data Safety Monitoring Board (DSMB) review recommended the INTEGRIS-IPF Phase 2a trial continue without modification and proceed to…
Mesoblast Prepares for Resubmission of Biologics License Application Late-Stage Clinical Pipeline Late-Stage Clinical Pipeline NEW YORK, Feb. 24, 2022 (GLOBE…
JSP191 is well tolerated with no treatment-related severe adverse events in 17 subjects with myelodysplastic syndrome (MDS) or acute myeloid…
CAMBRIDGE, Mass., Feb. 24, 2022 (GLOBE NEWSWIRE) — Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine…